专家共识声明：利奈唑胺的治疗药物监测与个体化用药
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid.
机构信息
Department of Pharmacy, Changxing People's Hospital, Changxing Branch, Second Affiliated Hospital of Zhejiang University School of Medicine, Huzhou, China.
Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Huzhou, China.
出版信息
Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. eCollection 2022.
Abstract
Linezolid is an oxazolidinone antibacterial drug, and its therapeutic drug monitoring and individualized treatment have been challenged since its approval. With the in-depth clinical research of linezolid, we have changed our attitude toward its therapeutic drug monitoring and our view of individualized treatment. On the basis of summarizing the existing clinical studies, and based on the practical experience of each expert in their respective professional fields, we have formed this expert consensus. Our team of specialists is a multidisciplinary team that includes pharmacotherapists, clinical pharmacology specialists, critical care medicine specialists, respiratory specialists, infectious disease specialists, emergency medicine specialists and more. We are committed to the safe and effective use of linezolid in patients in need, and the promotion of its therapeutic drug monitoring.
摘要
利奈唑胺是一种恶唑烷酮类抗菌药物，自批准以来，其治疗药物监测和个体化治疗一直受到挑战。随着利奈唑胺的深入临床研究，我们改变了对其治疗药物监测的态度和个体化治疗的看法。在总结现有临床研究的基础上，根据每位专家在各自专业领域的实践经验，我们形成了本专家共识。我们的专家组是一个多学科团队，包括药剂师、临床药理学专家、重症医学专家、呼吸科专家、传染病专家、急诊医学专家等。我们致力于确保需要的患者安全有效地使用利奈唑胺，并促进其治疗药物监测。
相似文献
1
Expert consensus statement on therapeutic drug monitoring and individualization of linezolid.
Front Public Health. 2022 Aug 10;10:967311. doi: 10.3389/fpubh.2022.967311. eCollection 2022.
2
Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.
Expert Opin Drug Metab Toxicol. 2016 May;12(5):533-44. doi: 10.1517/17425255.2016.1166204. Epub 2016 Mar 28.
3
Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
Expert Opin Drug Metab Toxicol. 2015;11(12):1849-59. doi: 10.1517/17425255.2015.1098617. Epub 2015 Oct 12.
4
Oxazolidinone antimicrobials: a patent review (2012-2015).
Expert Opin Ther Pat. 2016 May;26(5):591-605. doi: 10.1517/13543776.2016.1168807. Epub 2016 Apr 4.
5
Antibacterial Properties and Computational Insights of Potent Novel Linezolid-Based Oxazolidinones.
Pharmaceuticals (Basel). 2023 Mar 30;16(4):516. doi: 10.3390/ph16040516.
6
A validated UPLC-MS/MS method for the analysis of linezolid and a novel oxazolidinone derivative (PH027) in plasma and its application to tissue distribution study in rabbits.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 1;1040:89-96. doi: 10.1016/j.jchromb.2016.11.034. Epub 2016 Nov 27.
7
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation.
J Antimicrob Chemother. 2015 Jan;70(1):198-206. doi: 10.1093/jac/dku337. Epub 2014 Sep 1.
8
The discovery of linezolid, the first oxazolidinone antibacterial agent.
Curr Drug Targets Infect Disord. 2001 Aug;1(2):181-99. doi: 10.2174/1568005014606099.
9
Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class.
Curr Opin Investig Drugs. 2003 Feb;4(2):149-55.
10
Treatment options for vancomycin-resistant enterococcal infections.
Drugs. 2002;62(3):425-41. doi: 10.2165/00003495-200262030-00002.
引用本文的文献
1
Cutaneous nocardiosis in chronic renal insufficiency: Diagnostic and therapeutic considerations.
World J Clin Cases. 2025 Sep 16;13(26):108211. doi: 10.12998/wjcc.v13.i26.108211.
2
Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.
BMC Geriatr. 2025 Aug 6;25(1):597. doi: 10.1186/s12877-025-06241-9.
3
Pharmacokinetics and hematologic toxicity of linezolid in children: a prospective, two-center cohort study.
Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0029425. doi: 10.1128/aac.00294-25. Epub 2025 Jul 23.
4
Web-based automated therapeutic drug monitoring application for precision medicine in tuberculosis management.
Transl Clin Pharmacol. 2025 Jun;33(2):51-65. doi: 10.12793/tcp.2025.33.e9. Epub 2025 Jun 27.
5
Comparative analysis of thrombocytopenia incidence in patients treated with generic vs. brand-name linezolid: a cohort study utilizing hospital electronic medical records.
Front Pharmacol. 2025 Jun 18;16:1528633. doi: 10.3389/fphar.2025.1528633. eCollection 2025.
6
Drug-drug interaction of paroxetine on olanzapine and initial dosage optimization in patients with major depressive disorder based on population pharmacokinetics.
Front Psychiatry. 2025 May 13;16:1538996. doi: 10.3389/fpsyt.2025.1538996. eCollection 2025.
7
High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia.
Microbiol Spectr. 2025 Jul;13(7):e0249324. doi: 10.1128/spectrum.02493-24. Epub 2025 May 19.
8
Effective Management of a Skin and Soft Tissue Infection Caused by Community-Acquired MRSA Through Triple-Targeted Therapy Along with Aggressive Source Control: A Case Report.
Infect Dis Rep. 2025 Mar 24;17(2):27. doi: 10.3390/idr17020027.
9
Linezolid and tedizolid adverse effects: a review on serotonin syndrome, myelosuppression, neuropathies, and lactic acidosis.
Antimicrob Steward Healthc Epidemiol. 2025 Jan 27;5(1):e20. doi: 10.1017/ash.2024.487. eCollection 2025.
10
Population Pharmacokinetic/Pharmacodynamic Study of Linezolid in Hospital-Acquired Pneumonia Patients with Renal Insufficiency.
Drug Des Devel Ther. 2024 Nov 8;18:5073-5086. doi: 10.2147/DDDT.S474470. eCollection 2024.
本文引用的文献
1
UPLC-MS/MS Determination of Linezolid and Heme in Plasma of Infected Patients and Correlation Analysis.
Biomed Res Int. 2021 Jul 10;2021:6679076. doi: 10.1155/2021/6679076. eCollection 2021.
2
Simultaneous Measurement of 11 Antibiotics for Use in the Intensive Care Unit by Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.
Ther Drug Monit. 2022 Apr 1;44(2):308-318. doi: 10.1097/FTD.0000000000000911.
3
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.
Br J Clin Pharmacol. 2022 Feb;88(2):464-475. doi: 10.1111/bcp.14965. Epub 2021 Oct 10.
4
Liver function, quantified by the LiMAx test, as a predictor for the clinical outcome of critically ill patients treated with linezolid.
Technol Health Care. 2022;30(2):309-321. doi: 10.3233/THC-191847.
5
Linezolid resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Iran.
Acta Microbiol Immunol Hung. 2021 Jun 24. doi: 10.1556/030.2021.01490.
6
Trend in Antimicrobial Resistance of : Results from the China Antimicrobial Surveillance Network (CHINET) in the Last 15-Year-Period Reports (2005-2019).
Infect Drug Resist. 2021 Jun 10;14:2179-2181. doi: 10.2147/IDR.S318005. eCollection 2021.
7
Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.
Antibiotics (Basel). 2021 Apr 26;10(5):496. doi: 10.3390/antibiotics10050496.
8
Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.
Antimicrob Agents Chemother. 2021 May 18;65(6). doi: 10.1128/AAC.02490-20.
9
Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
BMC Pharmacol Toxicol. 2021 Mar 4;22(1):13. doi: 10.1186/s40360-021-00479-w.
10
Classification Tree Analysis Based On Machine Learning for Predicting Linezolid-Induced Thrombocytopenia.
J Pharm Sci. 2021 May;110(5):2295-2300. doi: 10.1016/j.xphs.2021.02.014. Epub 2021 Feb 17.
Zotero 插件